非布司他与别嘌醇治疗慢性肾脏病合并高尿酸血症的疗效比较

倪曼

摘要：目的  觀察非布司他与别嘌醇治疗慢性肾脏病合并高尿酸血症的临床疗效和安全性。方法  选取2018年8月～2019年8月在我院诊治的106例慢性肾脏病合并高尿酸血症患者为研究对象，将其随机分为对照组和观察组，各53例。对照组采用别嘌醇治疗，观察组采用非布司他治疗，比较两组临床治疗总有效率、治疗前后血肌酐、血尿酸水平、平均血尿酸降低50%、血肌酐降低10%时间及临床不良反应发生情况。结果  观察组治疗总有效率为94.33%，高于对照组的81.13%（P<0.05）;治疗后两组血肌酐、血尿酸水平均低于治疗前，且观察组低于对照组（P<0.05）;观察组平均血尿酸降低50%、血肌酐降低10%时间均短于对照组（P<0.05）;两组不良反应发生率比较，差异无统计学意义（P>0.05）。结论  非布司他治疗慢性肾脏病合并高尿酸血症疗效优于别嘌醇，有助于在短时间内改善血尿酸和血肌酐水平，且临床不良反应少，应用安全可靠。

关键词：非布司他;别嘌醇;慢性肾脏病;高尿酸血症

中图分类号：R589.7;R692                            文献标识码：A                             DOI：10.3969/j.issn.1006-1959.2020.15.043

文章编号：1006-1959（2020）15-0140-02

Abstract：Objective  To observe the clinical efficacy and safety of febuxostat tablets and allopurinol in the treatment of chronic kidney disease with hyperuricemia.Methods  A total of 106 patients with chronic kidney disease and hyperuricemia who were diagnosed and treated in our hospital from August 2018 to August 2019 were selected as the research subjects， and they were randomly divided into a control group and an observation group， with 53 cases in each. The control group was treated with allopurinol， and the observation group was treated with febuxostat tablets.The total effective rate of clinical treatment， blood creatinine and blood uric acid levels before and after treatment， average blood uric acid reduction by 50%， blood creatinine reduction by 10% time and clinical the occurrence of adverse reactions.Results  The total effective rate of treatment in the observation group was 94.33%， which was higher than 81.13% in the control group（P<0.05）. After treatment， the blood creatinine and blood uric acid levels of the two groups were lower than before treatment， and the observation group was lower than In the control group（P<0.05）; in the observation group， the average blood uric acid decreased by 50% and the blood creatinine decreased by 10% were shorter than the control group （P<0.05）; adverse reactions between the two groups incidence rate was not statistically significant （P>0.05）.Conclusion  Febuxostat tablets is more effective than allopurinol in the treatment of chronic kidney disease with hyperuricemia. It is helpful to improve blood uric acid and blood creatinine levels in a short period of time， with few clinical adverse reactions and safe and reliable application.